MHRA and NICE Open Call for Evidence on Digital Mental Health Resources

The consultation runs until 26 February 2027 and will help decide the direction of the programme's second phase.

UK regulators have opened a call for evidence on resources produced under the Wellcome-funded Digital Mental Health Technologies (DMHT) programme, with the survey running from 5 November 2026 to 26 February 2027.

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) are seeking feedback from developers and manufacturers of digital mental health technologies, healthcare professionals, researchers, policymakers, regulators, people with lived experience of mental health conditions, carers and members of the public.

What the evaluation covers

The survey forms part of the programme's Phase 1 evaluation. According to the two bodies, it is intended to establish how the resources have been received and used across the sector, and whether they have influenced users' knowledge, confidence, decision-making and professional practice.

The materials were developed to support the safe development, regulation, evaluation and adoption of digital mental health technologies, a category that includes mental health apps and other digital tools.

What happens next

Findings will be used to judge whether Phase 1 outputs met their intended objectives and to inform the direction of Phase 2. The MHRA and NICE said the feedback would help identify strengths, highlight areas for improvement and shape later work aimed at improving the safety and effectiveness of these technologies.

Stakeholders are invited to take part whether they have used the resources extensively, minimally or not at all.

DI

Dalia Ivanova

Dalia Ivanova covers sterile consumables, wound dressings, steam sterilizers, and endoscope reprocessors as an infection control, quality, and procurement editor for institutional readers. Her analyses track validated reprocessing cycles, sterility assurance parameters, service-contract terms, and total cost of ownership without asserting clinical outcomes or facility-specific results. She helps sterilization managers, infection-prevention teams, and purchasing groups compare reprocessing capacity, quality documentation, and lifecycle cost while excluding patient care advice and brand-only promotions.